APA (7th ed.) Citation

Jinger Lin, Xiangqi Chen, Min Luo, Qianwei Zhuo, Haosong Zhang, Nuo Chen, . . . Yue Han. (2024). Safety of tildrakizumab: A disproportionality analysis based on the FDA adverse event reporting system (FAERS) database from 2018-2023. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Jinger Lin, Xiangqi Chen, Min Luo, Qianwei Zhuo, Haosong Zhang, Nuo Chen, Yunqian Zhuo, and Yue Han. Safety of Tildrakizumab: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS) Database from 2018-2023. Frontiers Media S.A., 2024.

MLA (9th ed.) Citation

Jinger Lin, et al. Safety of Tildrakizumab: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS) Database from 2018-2023. Frontiers Media S.A., 2024.